Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale

Conclusion Further clinical studies are needed to identify patients with CMML who will benefit from this treatment. Micro-Abstract In a phase I dose-escalation study using eltrombopag to treat patients with myelodysplastic syndromes after hypomethylating agents failure, we observed that patients with chronic myelomonocytic leukemia may respond to eltrombopag. However, use in a subset of chronic myelomonocytic leukemia patients may be limited owing to leukocytosis and circulating blasts.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research